The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium

Body, Jean‐Jacques; Chevalier, Pierre; Günther, Oliver; Hechmati, Guy; Lamotte, M

doi:10.3111/13696998.2013.774279

Cited by 22 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone complications are associated with decreased survival and considerable morbidity, pain, impaired mobility, and decreased quality-of-life 3,[5][6][7][8][9][10] . Healthcare costs for patients with bone complications are substantial 3,[11][12][13][14][15][16] .…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Stopeck¹,

Brufsky

Kennedy

et al. 2019

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

Aims: Bone complications (also known as skeletal-related events [SREs]) pose significant health and financial burdens on patients with bone metastases. Denosumab demonstrated superiority over zoledronic acid in delaying the time to first SRE. This study examined the lifetime cost-effectiveness of denosumab vs zoledronic acid from both US payer and societal perspectives. Methods: This analysis used a lifetime Markov model and included patients with breast cancer, prostate cancer, and other solid tumors and bone metastases. The societal perspective included direct medical, direct non-medical, and indirect costs associated with denosumab and zoledronic acid; the payer perspective included direct medical costs only. Bone complication rates for each tumor type were estimated from three pivotal phase 3 studies and modified to reflect real-world incidence.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Stopeck¹,

Brufsky

Kennedy

et al. 2019

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies have reported costs of surgery for spinal metastases, and figures vary widely: €15,267 for both inpatient care and outpatient follow up in a Belgian study using Diagnosis Related Groups (DRG) codes and national tariffs 8 , an average inpatient cost of £16,885 in a United Kingdom study with patient-level actual costs, 9 but an average of $50,098 for direct costs to the hospital for inpatient stays in a San Francisco study, 10 and an average total of €87,814 over a lifetime horizon in a Danish study. 11 Detailed cost-utility analyses comparing surgical versus non-surgical approaches were performed by three authors.…”

Section: Introductionmentioning

confidence: 99%

Cost-Utility Analysis of Surgery and Radiotherapy for Symptomatic Spinal Metastases in a Belgian Specialist Center

Depreitere

Turner

Vandoren³

et al. 2019

World Neurosurgery

View full text Add to dashboard Cite

Cost-utility analysis of surgery and radiotherapy for symptomatic spinal utility analysis of surgery and radiotherapy for symptomatic spinal utility analysis of surgery and radiotherapy for symptomatic spinal utility analysis of surgery and radiotherapy for symptomatic spinal metastases in a Belgian specialist center. metastases in a Belgian specialist center. metastases in a Belgian specialist center. metastases in a Belgian specialist center.

show abstract

“…Further, BM can complicate patient treatment by necessitating targeted radiation or bone surgery . The presence of BM not only shortens the overall survival (OS) of these patients (median 6–12 months) , but also results in a significantly increased financial burden for patients and the healthcare system overall . Although primary bone tumors and BM have been extensively studied, the molecular differences between LUAD and BM remain largely unstudied.…”

Section: Introductionmentioning

confidence: 99%

Differentially expressed and survival‐related proteins of lung adenocarcinoma with bone metastasis

Yang

Sun

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Despite recent advances in targeted and immune‐based therapies, the poor prognosis of lung adenocarcinoma (LUAD) with bone metastasis (BM) remains a challenge. First, two‐dimensional gel electrophoresis (2‐DE) was used to identify proteins that were differentially expressed in LUAD with BM, and then matrix‐assisted laser desorption/ionization time of flight mass spectrometry (MALDI‐TOF‐MS) was used to identify these proteins. Second, the Cancer Genome Atlas (TCGA) was used to identify mutations in these differentially expressed proteins and Kaplan–Meier plotter (KM Plotter) was used to generate survival curves for the analyzed cases. Immunohistochemistry (IHC) was used to check the expression of proteins in 28 patients with BM and nine patients with LUAD. Lastly, the results were analyzed with respect to clinical features and patient's follow‐up. We identified a number of matched proteins from 2‐DE. High expression of enolase 1 (ENO1) (HR = 1.67, logrank P = 1.9E‐05), ribosomal protein lateral stalk subunit P2 (RPLP2) (HR = 1.77, logrank P = 2.9e‐06), and NME/NM23 nucleoside diphosphate kinase 2 (NME1‐NME2) (HR = 2.65, logrank P = 3.9E‐15) was all significantly associated with poor survival (P < 0.05). Further, ENO1 was upregulated (P = 0.0004) and calcyphosine (CAPS1) was downregulated (P = 5.34E‐07) in TCGA LUAD RNA‐seq expression data. IHC revealed that prominent ENO1 staining (OR = 7.5, P = 0.034) and low levels of CAPS1 (OR = 0.01, P < 0.0001) staining were associated with BM incidence. Finally, we found that LUAD patients with high expression of ENO1 and RPLP2 had worse overall survival. This is the first instance where the genes ENO1, RPLP2, NME1‐NME2 and CAPS1 were associated with disease severity and progression in LUAD patients with BM. Thus, with this study, we have identified potential biomarkers and therapeutic targets for this disease.

show abstract

The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium

Abstract: SREs add a substantial cost to the management of patients with bone metastases. Avoiding SREs can lead to important cost-savings for the healthcare payer.

Cited by 22 publications

References 18 publications

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Cost-Utility Analysis of Surgery and Radiotherapy for Symptomatic Spinal Metastases in a Belgian Specialist Center

Differentially expressed and survival‐related proteins of lung adenocarcinoma with bone metastasis

Contact Info

Product

Resources

About